Myocarditis cases hit levels two-to-three times higher in people with a second dose of the Moderna COVID-19 vaccine than the Pfizer BioNTech COVID-19 vaccine, researcher shows.
American College of Cardiology released a study last week that showed that males and females between 18 and 39 with the Moderna vaccine had higher rates of pericarditis and myocarditis. However, males ages 18-29 had the highest rates after receiving the second dose of Moderna.
The National Institutes of Health reports patients experience symptoms of chest pain, fever, fatigue, shortness of breath, and a rapid or irregular pulse, heart failure, shock or death.
Researchers pulled data from approximately 3 million people in British Columbia, Canada, and used participants over the age of 18 who were hospitalized for myocarditis, pericarditis, or myopericarditis within 21 days after having received a second Pfizer or Moderna between Jan. 1, 2021, and Sept. 9, 2021. The study excluded participants that had experienced myocarditis or pericarditis within one year before receiving the second dose of the COVID-19 vaccine.
“Within 21 days of the second dose, there were a total of 59 myocarditis cases, 21 after Pfizer and 31 after Moderna; and there were a total of 41 pericarditis cases: 21 after Pfizer and 20 after Moderna,” the study reads. “Researchers also looked at rates per million doses and the rate was 35.6 cases per million for Moderna and 12.6 per million for Pfizer—an almost threefold increase after Moderna shots vs. Pfizer.”
“Comparatively, rates of myocarditis in the general population in 2018, were 2.01 per million in people under age 40 and 2.2 per million in people over age 40,” the study added.
Guy Witberg, MD, MPH, a cardiologist at Rabin Medical Center in Petah-Tikva, Israel, said the study is “reassuring for vaccine safety,” adding it personalizes the approach to administering COVID-19 vaccines since further data shows myocarditis is a very rare adverse event after both vaccines.
[The study] should help put to rest ‘vaccine hesitancy’ due to concerns over cardiac adverse events,” Witberg said. “This is one of only a few direct comparisons of the two widely adopted mRNA vaccines, and its results have practical policy implications: for a substantial segment of the population suffering from cardiovascular disease.”
Moderna spokesman Luke Mircea-Willats emailed a statement to UPI saying, “mRNA-1273 has been administered to hundreds of millions of people worldwide and has been shown to be effective against both the original strain of the virus and its major variants.”
“Regulatory agencies around the world have stated that the benefits of COVID-19 mRNA vaccines significantly outweigh the risk across all age groups,” Mircea-Willats wrote. “Vaccination against COVID-19 continues to be a critical tool in overcoming the impacts of the global pandemic.”
Moderna told UPI myocarditis cases are a known but “very rare” risk associated with COVID-19 mRNA vaccines, adding, “when it does occur, cases are generally mild and resolve after a few days with treatment and rest.”
Moderna further notes population levels indicate that the risk of myocarditis after COVID-19 infection is much higher than after COVID-19 vaccination, adding it “shares all adverse events data with regulators and has a robust pharmacovigilance function, ensuring any adverse events are recorded and shared with the regulator in line with local regulations.”
The research drew mainstream media attention over the weekend.
Da’Vion Miller, 23, told NBC News that he initially experienced heart inflammation symptoms like chest pain, fatigue, shortness of breath, and dizziness two days after receiving his first Pfizer vaccine in October 2021.
Within the week after taking the shot, Miller was found unconscious in his bathroom in Detroit.
“It’s been a scary experience,” he said, adding he still experiences similar symptoms and has been in and out of the hospital following his diagnosis.
NBC reports Pfizer and the Pediatric Heart Network will conduct a study of people who were previously hospitalized with myocarditis associated with the vaccine over five years in the U.S. and Canada
Dr. Simone Gold, founder of America’s Frontline Doctors, who was de-platformed by social media giants Facebook, Twitter, and YouTube for posting information surrounding COVID-19 in 2020, said Pfizer and Moderna are launching clinical trials to track vaccine-caused myocarditis in teens and young adults.
We were censored for exposing the dangers of these experimental biological agents,” Gold said. “Now, even the creators of the “vaccines” are forced to recognize the truth.”
BREAKING: Pfizer and Moderna are launching clinical trials to track vaccine-caused myocarditis in teens/young adults.
We were censored for exposing the dangers of these experimental biological agents.
Now, even the creators of the “vaccines” are forced to recognize the truth.
— Dr. Simone Gold (@drsimonegold) November 13, 2022
